Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Breast 2Genitourinary 1

Conditions

Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × tetrathiomolybdate × Gastrointestinal × Clear all
NCT00176800 2016-08-22

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

University of Michigan Rogel Cancer Center

Phase 2 Completed
69 enrolled 7 charts
Gastrointestinal

Esophageal Neoplasms

NCT00176774 2012-02-07

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

University of Michigan Rogel Cancer Center

Phase 2 Completed
24 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡